JPH0685684B2 - Ganglioside-added milk powder - Google Patents
Ganglioside-added milk powderInfo
- Publication number
- JPH0685684B2 JPH0685684B2 JP61006285A JP628586A JPH0685684B2 JP H0685684 B2 JPH0685684 B2 JP H0685684B2 JP 61006285 A JP61006285 A JP 61006285A JP 628586 A JP628586 A JP 628586A JP H0685684 B2 JPH0685684 B2 JP H0685684B2
- Authority
- JP
- Japan
- Prior art keywords
- ganglioside
- milk powder
- milk
- added
- gangliosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dairy Products (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は乳製品の分野に属するもので、ガングリオシド
を添加して成る粉乳に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial field of application] The present invention belongs to the field of dairy products and relates to milk powder to which ganglioside is added.
ガングリオシド類は、神経系組織の細胞膜上に多く含ま
れている、Ｎ−アセチルノイラミン酸を含有するスフィ
ンゴ糖脂質の総称である。ガングリオシド類の生理活性
としては細菌毒素の中和活性、インターフエロンやホル
モンの受容体活性、神経細胞の増殖促進活性等が知られ
ている。しかし、ガングリオシド類を天然物から調製す
ることが困難であって、その入手が容易でないこと、お
よび上述した生理活性もin vitroで確認されたものであ
って、生体内での活性については未だ確認されていない
等の理由により、ガングリオシド類を食品へ利用するこ
とは行われていないのが現状である。Gangliosides are a general term for glycosphingolipids containing N-acetylneuraminic acid, which are abundant on the cell membranes of nervous system tissues. Known physiological activities of gangliosides are neutralizing activity of bacterial toxins, receptor activity of interferons and hormones, and nerve cell growth promoting activity. However, it is difficult to prepare gangliosides from natural products, their availability is not easy, and the above-mentioned physiological activities have been confirmed in vitro, and their activity in vivo has not been confirmed. Under the present circumstances, gangliosides have not been used for foods because of not being used.
本発明者は人乳および牛乳に含まれているガングリオシ
ド類の乳児栄養生理的意義について検討した結果、人乳
および牛乳ガングリオシドが病原性微生物やウィルスが
腸粘膜細胞に付着するのを阻止する活性を有するとの知
見を得た。As a result of examining the infant nutritional physiological significance of gangliosides contained in human milk and milk, the present inventor has found that human milk and milk ganglioside have an activity of preventing pathogenic microorganisms and viruses from adhering to intestinal mucosal cells. I got the knowledge that I have it.
即ち、免疫機能が未発達な乳児において、乳ガングリオ
シドが病原性微生物やウィルスの感染防御因子として重
要な作用をもっていることが明らかとなった。That is, it has been clarified that breast ganglioside has an important action as a defense factor against infection of pathogenic microorganisms and viruses in infants with undeveloped immune function.
従って、本発明は、感染防御因子であるガングリオシド
を粉乳に配合することにより、免疫機能が未発達な乳児
にガングリオシドを有効に補給し得る粉乳を提供するこ
とを目的とする。Therefore, an object of the present invention is to provide a powdered milk that can effectively supplement gangliosides to an infant with an undeveloped immune function by incorporating ganglioside, which is an infection protective factor, into the powdered milk.
本発明は、ガングリオシドを添加して成る粉乳を提供す
るものである。The present invention provides milk powder containing ganglioside.
本発明によれば、調製粉乳が牛乳と異なり乳脂肪を精製
植物油で置換しているため、ガングリオシド類の含有量
が極端に少ないので、上述のようにin vivoでも活性が
証明された感染防御因子であるガングリオシドを粉乳に
添加することにより、免疫機能が未発達な乳児にガング
リオシドを有効に補給し得る粉乳を提供することができ
る。また、ガングリオシドの添加により、高い活性を持
つ粉乳を作る事ができる。According to the present invention, the modified milk replaces milk fat with refined vegetable oil unlike cow's milk, so that the content of gangliosides is extremely low. By adding ganglioside, which is the above, to milk powder, it is possible to provide milk powder that can effectively supplement ganglioside to an infant with an undeveloped immune function. In addition, powdered milk having high activity can be produced by adding ganglioside.
以下、本発明を詳しく説明する。Hereinafter, the present invention will be described in detail.
本発明の特徴は、粉乳にガングリオシドを添加したこと
にある。ここでいうガングリオシドは、一般式（NANA）
ｎ−Gal−Glc−セラミド（ただし、式中NANAはＮ−アセ
チルノイラミン酸、Galはガラクトース、Glcはグルコー
ス、ｎは１又は２の整数を示す）で表される。ガングリ
オシドは例えば日本生化学界編「生化学実験講座」３、
脂質の化学、（東京化学同人、1974年11月25日発行）に
記載される方法により得られる。The feature of the present invention is that ganglioside is added to milk powder. The ganglioside here is the general formula (NANA)
n-Gal-Glc-ceramide (wherein NANA is N-acetylneuraminic acid, Gal is galactose, Glc is glucose, and n is an integer of 1 or 2). Gangliosides are, for example, “Biochemistry Experiment Course” edited by the Japanese Society of Biochemistry 3,
It is obtained by the method described in Lipid Chemistry, (Tokyo Kagaku Dojin, published November 25, 1974).
ガングリオシドの粉乳に対する添加量は0.5mg重量％以
上あれば充分な効果があり、特に好ましくは1.0〜50mg
重量％である。50mg重量％を超えても効果はあまり変わ
らない。If the amount of ganglioside added to milk powder is 0.5 mg% by weight or more, there is sufficient effect, and particularly preferably 1.0-50 mg
% By weight. The effect does not change much even if it exceeds 50 mg% by weight.
病原性大腸菌およびロタウィルスを用いて、牛乳ガング
リオシドの感染防御作用を検討した結果を以下に述べ
る。The results of examining the protective effect of milk ganglioside against infection using pathogenic Escherichia coli and rotavirus are described below.
単層培養したヒト小腸由来株化細胞407株上に、ガング
リオシド2mg重量％を含むトリチウムラベルした大腸菌
懸濁液を加えて、30℃で１時間反応させた後、細胞に吸
着した大腸菌量を液体シンチレーションカウンターで測
定した。A tritium-labeled E. coli suspension containing 2 mg% by weight of ganglioside was added to 407 human small intestine-derived cell lines that had been monolayer-cultured, and the mixture was reacted at 30 ° C for 1 hour. It measured with the scintillation counter.
なお、対照としては、ガングリオシドを含まない大腸菌
懸濁液を用いて同様の操作を行った。第１図に示した結
果から明らかなように、対照は反応時間の経過と共に細
胞に吸着した大腸菌数が急激に増加するのに対して、ガ
ングリオシドを添加すると細胞に吸着する大腸菌量が、
対照と比べて減少した。As a control, the same operation was performed using an E. coli suspension containing no ganglioside. As is clear from the results shown in FIG. 1, in the control, the number of E. coli adsorbed to the cells increased rapidly with the passage of reaction time, whereas in the case of adding ganglioside, the amount of E. coli adsorbed to the cells was
It decreased compared to the control.
第２図にロタウィルスを用いて同様の試験を行った結果
を示した。この図から、大腸菌と同様にガングリオシド
によりロタウィルスの細胞付着が阻止されたことが判
る。FIG. 2 shows the results of the same test using rotavirus. From this figure, it can be seen that the gangliosides blocked the rotavirus cell attachment as in E. coli.
次に、育児用粉乳に対して種々の量のガングリオシドを
添加配合したものを、試験動物として日令21日のラット
に給与して、感染試験を行った。すなわち、ガングリオ
シドを０〜100mg重量％添加した粉乳を給与したラット
に病原性大腸菌を一定量経口投与して、下痢の発生率を
測定した結果を第１表に示した。Next, a mixture of various amounts of ganglioside added to infant milk powder was fed as a test animal to a rat on the 21st day of the age, and an infection test was conducted. That is, Table 1 shows the results of measuring the incidence of diarrhea by orally administering a certain amount of pathogenic Escherichia coli to rats fed powdered milk containing 0 to 100 mg% by weight of ganglioside.
表から明らかなようにガングリオシドを0.5mg重量％以
上を添加すると、無添加の場合に比べて、病理性大腸菌
による下痢の発生率が低下した。しかし、50mg重量％よ
り多く配合しても、特に下痢の低下が見られない。As is clear from the table, when gangliosides were added in an amount of 0.5 mg% by weight or more, the incidence of diarrhea caused by pathogenic Escherichia coli was decreased as compared with the case where no addition was made. However, diarrhea is not particularly reduced even when the amount is more than 50 mg% by weight.
第１表 ガングリオシドの添加量（mg％） 下痢の発生率（％） ０ 100 0.5 95 １ 50 10 30 50 20 100 20 本発明は、ガングリオシドを添加配合する粉乳として
は、前述したように免疫機能の未発達な乳児、特に新生
児の感染防御の見地から、主として育児用調製粉乳、未
熟児用粉乳を対象とするものであるが、その他にフォロ
ーアップミルク、治療用特殊粉乳および一般粉乳も対象
となるのは勿論である。更に、チーズ等の乳製品、健康
食品および一般食料品もガングリオシドの添加の対象と
なり、健康を保持するための生理活性を強化した製品を
得ることが出来る。Table 1 Addition amount of ganglioside (mg%) Incidence of diarrhea (%) 0 100 0.5 95 1 50 10 30 50 20 100 20 The present invention, as described above, improves the immune function of the milk powder containing ganglioside. From the standpoint of protection against infection of underdeveloped infants, especially newborn infants, it mainly targets infant formula, infant milk powder, but also follow-up milk, special therapeutic milk powder and general milk powder. Of course. Furthermore, dairy products such as cheese, health foods, and general food products are also targets for the addition of gangliosides, and products having enhanced physiological activity for maintaining health can be obtained.
本発明によれば、ガングリオシドは、前述のとおり、病
原性微生物やウィルスの感染阻止活性を有することか
ら、上述したように、治療用特殊粉乳、フォローアップ
ミルクおよび一般粉乳に添加することにより、これら粉
乳の生理活性を高めることが可能となった。According to the present invention, the ganglioside has the activity of inhibiting the infection of pathogenic microorganisms and viruses as described above, and thus, as described above, by adding it to the therapeutic special milk powder, the follow-up milk and the general milk powder, these It became possible to enhance the physiological activity of milk powder.
以下、実施例を示して本発明を具体的に説明する。Hereinafter, the present invention will be specifically described with reference to examples.
粉乳への添加配合 牛乳ガングリオシドを添加した粉乳を給与したラットを
用いて、病原性大腸菌を経口投与し、下痢の発生率を測
定した。牛乳ガングリオシドは特開昭60-72819号公報に
記載される方法に従って得られたものを使用した。Addition to powdered milk The pathogenic Escherichia coli was orally administered to rats fed with milk powder added with milk ganglioside, and the incidence of diarrhea was measured. The milk ganglioside used was obtained according to the method described in JP-A-60-72819.
試験方法： 日令７日のラット24匹から成る群を試験動物として用
い、その１群には上記ガングリオシド添加粉乳を投与
し、他の１群にはガングリオシドを添加していない現行
の育児用粉乳を投与した。それぞれの群について、病原
性大腸菌を経口投与した後、その下痢の発生率を測定し
た。結果を第２表に示した。Test method: A group of 24 rats aged 7 days was used as a test animal, and one group was administered with the above-mentioned ganglioside-added milk powder, and the other group was the current baby milk powder without ganglioside addition. Was administered. For each group, the incidence of diarrhea was measured after oral administration of pathogenic E. coli. The results are shown in Table 2.
表にみられるように、ガングリオシド添加粉乳を投与し
た群では、添加しない群より下痢の発生率が有意に低か
った。As shown in the table, the incidence of diarrhea was significantly lower in the group administered with ganglioside-added milk powder than in the group not added.
【図面の簡単な説明】 第１図は、ガングリオシド添加による大腸菌の細胞吸着
阻止の効果を示すグラフ、 第２図は、ガングリオシド添加によるロタウィルスの細
胞吸着阻止の効果を示すグラフである。 ○……ガングリオシド、×……無添加BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the effect of E. coli cell adsorption inhibition by the addition of ganglioside, and FIG. 2 is a graph showing the effect of rotavirus cell adsorption inhibition by the addition of ganglioside. ○ …… Ganglioside, × …… Additive-free
Claims (2)
（ただし、式中NANAはＮ−アセチルノイラミン酸、Gal
はガラクトース、Glcはグルコース、ｎは１又は２の整
数を示す）で表されるガングリオシドを添加して成る粉
乳。Claims: 1. General formula (NANA) n-Gal-Glc-ceramide (wherein NANA is N-acetylneuraminic acid, Gal
Is galactose, Glc is glucose, and n is an integer of 1 or 2), and milk powder is added.
上である特許請求の範囲第１項記載の粉乳。2. The milk powder according to claim 1, wherein the amount of ganglioside added is 0.5 mg% by weight or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61006285A JPH0685684B2 (en) | 1986-01-17 | 1986-01-17 | Ganglioside-added milk powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61006285A JPH0685684B2 (en) | 1986-01-17 | 1986-01-17 | Ganglioside-added milk powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62166841A JPS62166841A (en) | 1987-07-23 |
| JPH0685684B2 true JPH0685684B2 (en) | 1994-11-02 |
Family
ID=11634119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61006285A Expired - Fee Related JPH0685684B2 (en) | 1986-01-17 | 1986-01-17 | Ganglioside-added milk powder |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0685684B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020166527A1 (en) | 2019-02-12 | 2020-08-20 | めぐみ 田中 | Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2821770B2 (en) * | 1989-07-17 | 1998-11-05 | 雪印乳業株式会社 | Baby milk powder with the ability to neutralize bacterial toxins |
| JP2001233773A (en) * | 2000-02-22 | 2001-08-28 | Toko Yakuhin Kogyo Kk | Antiviral agent |
| JP2007055921A (en) * | 2005-08-23 | 2007-03-08 | Nagasaki Univ | Binder to vacuolation toxin of helicobacter pylori |
| US20080003329A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Enriched infant formulas |
| CN101902918A (en) | 2007-10-19 | 2010-12-01 | 方塔拉合作集团有限公司 | Keep or increase the method for growth or cognitive development |
| CN103859041A (en) * | 2014-03-20 | 2014-06-18 | 深圳市味奇生物科技有限公司 | Powder fortified with calcium applicable to the nutritional supplement of babies and preparation method of powder |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59184197A (en) * | 1983-04-01 | 1984-10-19 | Snow Brand Milk Prod Co Ltd | Preparation of oligosaccharide of sialic acid bond |
| JPS6072819A (en) * | 1983-09-29 | 1985-04-24 | Yakult Honsha Co Ltd | Neutralizing agent for cycotoxin |
| JPS61152233A (en) * | 1984-12-26 | 1986-07-10 | Snow Brand Milk Prod Co Ltd | Powdered milk blended with sialic acid |
-
1986
- 1986-01-17 JP JP61006285A patent/JPH0685684B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020166527A1 (en) | 2019-02-12 | 2020-08-20 | めぐみ 田中 | Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62166841A (en) | 1987-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schwarz et al. | Fluorine requirement for growth in the rat | |
| EP0579901B1 (en) | Use of a feed additive for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation | |
| Geiger et al. | The role of the time factor in feeding supplementary proteins | |
| Srikantia et al. | Megaloblastic anaemia of infancy and vitamin B12 | |
| JPH05163160A (en) | Nutrient preparation for prevention and treatment of infectious disease caused by immune depression | |
| Teply et al. | The intestinal synthesis of niacin and folic acid in the rat | |
| Gullberg | Possible Influence of Vitamin B12-Binding Protein in Milk on the Intestinal Flora in Breast-Fed Infants: I. B12-Binding Proteins in Human and Bovine Milk | |
| Rutishauser et al. | The effect of a traditional low-fat diet on energy and protein intake, serum albumin concentration and body-weight in Ugandan preschool children | |
| EP0035882B1 (en) | Method for producing iodine-enriched eggs | |
| JPH0685684B2 (en) | Ganglioside-added milk powder | |
| JPH06101988B2 (en) | The use of certain compounds as growth promoters in livestock feed for improved feed utilization and improved meat composition. | |
| JPH0340010B2 (en) | ||
| PAINE et al. | The dietary phenylalanine requirements and tolerances of phenylketonuric patients | |
| IE832957L (en) | Addition of vitamin k to ingestible compositions or¹toothpastes. | |
| Sporn et al. | Growth and reproduction in rats on synthetic rations. | |
| EP0134112B1 (en) | Pharmaceutical composition for prophylaxis or treatment of ketosis in livestock | |
| JPH05252899A (en) | Increasing agent for omega-3-based fatty acid in biological tissue and nutritive composition containing the same | |
| JPS6365285B2 (en) | ||
| JP2516794B2 (en) | Baby formula containing vitamin D metabolites | |
| Sober et al. | Nutrition of the guinea pig | |
| Tucker et al. | Nucleic acid content of rat mammary gland after teat ligation. | |
| Ho et al. | Studies on lymphatic absorption of and the availability of riboflavin from bovine milk xanthine oxidase | |
| Harris et al. | Calcium kinetics in vitamin D deficiency rickets: II. Intestinal handling of calcium | |
| Stookey et al. | Relationship between fluoride deposition and metastatic calcification in soft tissues of rat and guinea pig | |
| Cassimos et al. | Continuous intravenous infusion of calcium in vitamin D deficient rickets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |